Celerion, Inc — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$4,957,960	1
2024	Research	$1,559,893	2
2022	Research	$2,476,183	16
2021	Research	$14,368,076	50
2020	Research	$6,734,381	47
2019	Research	$5,565,031	99

Breakdown

Who paid Research payments · program years 2019–2025

Hexal AG $11,796,590 48 payments
Merck Sharp & Dohme Corporation $10,364,883 116 payments
E.R. Squibb & Sons, L.L.C. $6,517,853 3 payments
Jazz Pharmaceuticals Inc. $5,615,176 19 payments
Novo Nordisk AS $1,367,022 29 payments

Studies the money was for Research payments · program years 2019–2025

Cgpn017b12101 $11,770,994 47 payments
A Phase 1, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986419 (Part 1) and a Phase 1 Randomized, Double-blind, Positive- controlled, Placebo-controlled, Parallel, Nested-crossover (moxifloxacin-placebo) Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants $4,957,960 1 payment
A Phase 1, Single-Blind, Parallel-Cohort, Within-Subject Multiple Dose Escalation Study to Characterize Pharmacokinetics, Safety and Tolerability of Cx-8998 Formulations in Healthy Older Adult Subjects $4,486,904 11 payments
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults $2,552,168 6 payments
An Open-Label, Two-Arm, Parallel-Group Bioavailability Study to Demonstrate Comparable Systemic Exposure Between Nexplanon Manufactured Using Ethylene Vinyl Acetate From Two Different Suppliers in Healthy Female Participants. $2,445,858 21 payments
A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants $1,495,136 1 payment
A Phase 1, Open-Label, Single Oral Dose Study to Determine Absorption, Metabolism, and Excretion of [14 C]-Jzp385 in Healthy Male Participants $1,121,314 7 payments
A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Islatravir MK-8591 on the QTc Interval in Healthy Adult Participants $802,645 1 payment
Nn9775-4398 $790,439 16 payments
An Open-Label Trial to Assess the Effect of Multiple Doses of Rifabutin on the Single-Dose Pharmacokinetics of MK-8507 in Healthy Adult Participants. $637,271 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.